Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Heise

Showing results (61-70 of 150) with videos related to

Pageof 15
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2006
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp studyKlaus Rave, Leszek Nosek, John Posner, et al.
Diabetes Care|August 24, 2014
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254Ulrike Graefe-Mody, Christian Friedrich, Maximilian von Eynatten, et al.
Diabetes Care|August 27, 2005
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetesThomas Danne, Reinhard H A Becker, Tim Heise, et al.
Diabetes|May 27, 2004
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetesTim Heise, Leszek Nosek, Birgitte Biilmann Rønn, et al.
Plos One|March 18, 2011
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR TrialStephan Martin, Christian Herder, Nanette C Schloot, et al.
Clinical Pharmacokinetics|November 8, 2018
Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes MellitusHanne Haahr, Thomas R Pieber, Chantal Mathieu, et al.
Diabetes/Metabolism Research and Reviews|May 26, 2005
Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp studyKlaus Rave, Sabine Flesch, W Nikolaus Kühn-Velten, et al.
BMC Health Services Research|November 17, 2020
Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studiesConstance Stegbauer, Camilla Falivena, Ariadna Moreno, et al.
Clinical Pharmacokinetics|November 24, 2016
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes MellitusTim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann, et al.
Pageof 15

Showing results (61-70 of 150) with videos related to

Sort By:
Pageof 15
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2006
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp studyKlaus Rave, Leszek Nosek, John Posner, et al.
Diabetes Care|August 24, 2014
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254Ulrike Graefe-Mody, Christian Friedrich, Maximilian von Eynatten, et al.
Diabetes Care|August 27, 2005
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetesThomas Danne, Reinhard H A Becker, Tim Heise, et al.
Diabetes|May 27, 2004
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetesTim Heise, Leszek Nosek, Birgitte Biilmann Rønn, et al.
Plos One|March 18, 2011
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR TrialStephan Martin, Christian Herder, Nanette C Schloot, et al.
Clinical Pharmacokinetics|November 8, 2018
Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes MellitusHanne Haahr, Thomas R Pieber, Chantal Mathieu, et al.
Diabetes/Metabolism Research and Reviews|May 26, 2005
Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp studyKlaus Rave, Sabine Flesch, W Nikolaus Kühn-Velten, et al.
BMC Health Services Research|November 17, 2020
Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studiesConstance Stegbauer, Camilla Falivena, Ariadna Moreno, et al.
Clinical Pharmacokinetics|November 24, 2016
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes MellitusTim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann, et al.
Pageof 15